# Jiangsu Yaohai Bio-pharmaceutical Co.Ltd.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-yaohai-bio-pharmaceutical-co-ltd

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.yaohai-bio.com
- Total disclosed funding: $29M
- Latest round: Series B (Nov 21, 2022)
- Investors on record: 3

## About

Based in Taizhou, China, and established in 2010, Jiangsu Yaohai Bio-pharmaceutical Co.Ltd. operates as a CDMO service provider focusing on microbial expression systems. So far, it has completed 4 US-China dual reporting projects, 2 Australian registration projects, and 2 Phase III clinical projects, with partnerships with Tasly Holding Group, Yabao, Sinopharm, etc.

The company's businesses can be categorized into CDMO services, quality management services, and sales of reagents. Some main products of the reagents category include virus sampling tubes and enterokinase. It provides CMO services for pilot scale-up and pilot production as well as fermentation, purification, and formulation for registration, clinical phase I, II, and III samples.

## Funding rounds

- Series B, Nov 21, 2022, $14M — China International Capital Corporation, Qiandao Investment Fund Management
- Series B, Nov 18, 2020, $15M — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series B